Expertise in
2
conditions

Bjornar Gilje

Stavanger, NO 
Expertise in
2
conditions
Stavanger, NO 
OverviewLocationsClinical Research

Overview

Bjornar Gilje practices in Stavanger, Norway. Gilje is highly rated in 2 conditions, according to our data. Their top areas of expertise are Triple-Negative Breast Cancer, Breast Cancer, Pancreatic Cancer, and Pancreatic Ductal Adenocarcinoma.

Their clinical research consists of co-authoring 49 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Stavanger, Norway

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

ALICE: a Randomized Placebo-controlled Phase II Study Evaluating Atezolizumab Combined with Immunogenic Chemotherapy in Patients with Metastatic Triple-negative Breast Cancer
ALICE: a Randomized Placebo-controlled Phase II Study Evaluating Atezolizumab Combined with Immunogenic Chemotherapy in Patients with Metastatic Triple-negative Breast Cancer
Enrollment Status: Completed
Publish Date: October 15, 2024
Intervention Type: Other, Drug
Study Drugs: Atezolizumab, Pegylated liposomal doxorubicin, Cyclophosphamide
Study Phase: Phase 2
Treatment of Patients With Advanced Breast Cancer Harboring TP53 Mutations With Dose-dense Cyclophosphamide - the p53 Breast Cancer Trial
Treatment of Patients With Advanced Breast Cancer Harboring TP53 Mutations With Dose-dense Cyclophosphamide - the p53 Breast Cancer Trial
Enrollment Status: Active_not_recruiting
Publish Date: January 12, 2024
Intervention Type: Drug
Study Drug: Cyclophosphamide
Study Phase: Phase 2
PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial
PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2021
Intervention Type: Radiation, Drug, Procedure
Study Drugs: Neoadjuvant Tamoxifen+Goserelin, Neoadjuvant Letrozole, Neoadjuvant Docetaxel+Cyclophosphamide, Neoadjuvant Docetaxel, Neoadjuvant Docetaxel+Trastuzumab+Pertuzumab, Neoadjuvant, Neoadjuvant Olaparib, Neoadjuvant Cyclophosphamide, Adjuvant Trastuzumab, Adjuvant Letrozole, Adjuvant Tamoxifen+Goserelin, Adjuvant Palbociclib, Adjuvant Epirubicin+Cyclophosphamide
Study Phase: Phase 2
View 2 Less Clinical Trials

49 Total Publications

Tumor-agnostic detection of circulating tumor DNA in patients with advanced pancreatic cancer using targeted DNA methylation sequencing and cell-free DNA fragmentomics.
Tumor-agnostic detection of circulating tumor DNA in patients with advanced pancreatic cancer using targeted DNA methylation sequencing and cell-free DNA fragmentomics.
Journal: Molecular oncology
Published: July 11, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Gilje's expertise for a condition
ConditionClose
      View All 7 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile